Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
featured
Acne, psoriasis, atopic dermatitis

Acne, psoriasis, atopic dermatitis

  • 1950 views
  • 25 Mar, 2021
  • 1 location
Efficacy Safety and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

Safety and Efficacy study of AVT04 (Alvotech Biosimilar to Ustekinumab), in patients with moderate to severe plaque psoriasis

plaque psoriasis
ustekinumab
  • 4 views
  • 23 Jun, 2021
  • 1 location
A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

The purpose of the study is to evaluate the efficacy, safety, and immunogenicity of ABP 654 compared with ustekinumab in participants with moderate to severe plaque psoriasis.

  • 0 views
  • 26 Jun, 2021
  • 158 locations
A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants

The purpose of this study is to evaluate the pharmacokinetic (PK) and bioequivalence (BE) of ustekinumab administered by a single subcutaneous (SC) injection with Device 1 or Device 2 in healthy

  • 0 views
  • 25 May, 2021
  • 2 locations
Pharmacokinetics Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)

globally as a proposed biosimilar to the reference product Stelara (ustekinumab) for subcutaneous (SC) use. This is a first-in-human (FIH) clinical study with AVT04. The study aims to demonstrate

oophorectomy
body mass index
hysterectomy
ustekinumab
  • 0 views
  • 23 Jun, 2021
  • 1 location
Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis

that exists during GCA. Ustekinumab, which is a monoclonal antibody blocking the subunit common to IL-12 and IL-23 (p40), blocks the Th1 and Th17 responses, and could therefore be an excellent

  • 0 views
  • 25 Jan, 2021
  • 1 location
Stelara fOr ChRonic AntibioTic rEfractory pouchitiS

To evaluate the efficacy and safety of ustekinumab in the treatment of chronic antibiotic refractory and relapsing pouchitis.

  • 0 views
  • 06 May, 2021
  • 2 locations
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy Subjects

This is a randomised, double-blind, three-arm, parallel group, single-dose study to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of SB17 compared to EU sourced Stelara and US sourced Stelara in healthy subjects

  • 0 views
  • 25 Mar, 2021
  • 1 location
A Double-blind Study to Compare the Efficacy Safety and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara in Patients With Moderate-to-Severe Plaque Psoriasis

This is a randomized, double-blind, multicenter study to evaluate the efficacy, safety, and immunogenicity of FYB202 compared to Stelara in patients with Moderate-to-Severe Plaque Psoriasis.

  • 0 views
  • 26 Jan, 2021
  • 2 locations
A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)

). Ustekinumab, a humanized anti-p40 monoclonal antibody, is able to target both IL-12 and IL-23 pathways, thus disrupting Th1 and Th17 immune responses. Decreasing the dose as well as the duration of

  • 4 views
  • 22 Apr, 2021
  • 3 locations